Patents by Inventor Thomas Gant

Thomas Gant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190083484
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: October 17, 2018
    Publication date: March 21, 2019
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Patent number: 9814708
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 14, 2017
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20170087147
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: October 6, 2016
    Publication date: March 30, 2017
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Patent number: 9550780
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: January 24, 2017
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20160235733
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 18, 2016
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20160222008
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: March 16, 2016
    Publication date: August 4, 2016
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Patent number: 9346800
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: May 24, 2016
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Patent number: 9296739
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: March 29, 2016
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Patent number: 9233959
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: January 12, 2016
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20150004231
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 1, 2015
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20140341994
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: April 4, 2014
    Publication date: November 20, 2014
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20140336386
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: September 18, 2013
    Publication date: November 13, 2014
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20080103189
    Abstract: Disclosed herein are substituted indoles of Formula I, processes of preparation there of, pharmaceutical compositions thereof, and methods of their use there of.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 1, 2008
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventors: Thomas Gant, Sepehr Sarshar
  • Publication number: 20080045588
    Abstract: Provided herein are substituted amphetamines, processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use for the treatment and/or management of trauma associated with a terminal disease, a post-traumatic-stress-disorder, or a psychological disorder.
    Type: Application
    Filed: August 2, 2007
    Publication date: February 21, 2008
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventors: Thomas Gant, Sepehr Sarshar
  • Publication number: 20080045504
    Abstract: This invention relates to novel amino substituted benzonitrile derivatives and to pharmaceutical compositions containing the novel amino substituted benzonitrile derivatives. This invention also relates to methods of treatment using amino substituted benzonitrile derivatives to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, and treat bone fracture and muscle damage in mammals, including humans.
    Type: Application
    Filed: April 29, 2005
    Publication date: February 21, 2008
    Applicant: PFIZER PRODUCTS INC.
    Inventors: Thomas Gant, Bruce Lefker, Hua Ke, James O'Malley, Roger Hill
  • Publication number: 20070287734
    Abstract: The present disclosure is directed to modulators of CB-1 type receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of obesity, metabolic syndrome, dyslipidemia, glucose imbalance, the inability to maintain weight loss, insulin resistance, a cardiovascular disorder, memory loss, drug dependence, a depressive disorder, a panic disorder, an obsessive-compulsive disorder, anxiety, post-traumatic stress syndrome, and any other condition in which it is beneficial to inhibit, inversely agonize or modulate a cannabinoid receptor are described.
    Type: Application
    Filed: June 11, 2007
    Publication date: December 13, 2007
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventors: Thomas GANT, Sepehr Sarshar
  • Publication number: 20070155820
    Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
    Type: Application
    Filed: November 22, 2006
    Publication date: July 5, 2007
    Applicant: AUSPEX Pharmaceuticals, Inc.
    Inventors: Thomas Gant, Sepehr Sarshar
  • Publication number: 20070149622
    Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
    Type: Application
    Filed: November 30, 2006
    Publication date: June 28, 2007
    Applicant: AUSPEX Pharmaceuticals, Inc.
    Inventors: Thomas Gant, Sepehr Sarshar
  • Publication number: 20070112031
    Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
    Type: Application
    Filed: November 13, 2006
    Publication date: May 17, 2007
    Inventors: Thomas Gant, Sepehr Sarshar
  • Publication number: 20070082929
    Abstract: Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.
    Type: Application
    Filed: October 4, 2006
    Publication date: April 12, 2007
    Inventors: Thomas Gant, Sepehr Sarshar